Abstract
Down syndrome (DS) or trisomy of chromosome 21 is the most prevalent cause of genetic intellectual disability affecting approximately 1 in 700 live births. Most DS cases are caused by full triplication of chromosome 21, and a small number of cases arise from mosaicism or chromosomal translocations, resulting in multiple medical and physical manifestations. Common characteristics of individuals with DS include skeletal anomalies, craniofacial alterations, hypotonia, increased incidence of congenital heart disease and seizures, abnormalities of the gastrointestinal tract, thyroid dysfunction, and premature aging [1]. Additional clinical features include altered folate metabolism and hormone imbalances [2, 3]. Neurological changes include reduced brain mass, impaired neuronal differentiation, aberrant dendritic spine morphology, and defects in synaptic plasticity [4]. Most middle-aged individuals with DS develop Alzheimer’s disease (see chapter “Alzheimer’s disease”) due to increased expression of the amyloid precursor protein gene located on chromosome 21 [5]. Alterations in reactive oxygen species (ROS) and energy metabolism have long been associated with the development and progression of DS neuropathology [6]. This section focuses on the role of oxidative stress, mitochondrial dysfunction, and hypothyroidism in DS.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Roizen NJ, Patterson D (2003) Down’s syndrome. Lancet 361:1281–1289
Shaw CK, Thapalial A, Nanda S, Shaw P (2006) Thyroid dysfunction in Down syndrome. Kathmandu Univ Med J (KUMJ) 4:182–186
Patterson D (2009) Molecular genetic analysis of Down syndrome. Hum Genet 126:195–214
Lott IT (2012) Neurological phenotypes for Down syndrome across the life span. Prog Brain Res 197:101–121
Mann DM, Esiri MM (1989) The pattern of acquisition of plaques and tangles in the brains of patients under 50 years of age with Down’s syndrome. J Neurol Sci 89:169–179
Coskun PE, Busciglio J (2012) Oxidative stress and mitochondrial dysfunction in Down’s syndrome: relevance to aging and dementia. Curr Gerontol Geriatr Res 2012:383170
Lott IT, Head E, Doran E, Busciglio J (2006) Beta-amyloid, oxidative stress and down syndrome. Curr Alzheimer Res 3:521–528
Brooksbank BW, Martinez M, Balazs R (1985) Altered composition of polyunsaturated fatty acyl groups in phosphoglycerides of Down’s syndrome fetal brain. J Neurochem 44:869–874
Slonim DK, Koide K, Johnson KL, Tantravahi U, Cowan JM, Jarrah Z, Bianchi DW (2009) Functional genomic analysis of amniotic fluid cell-free mRNA suggests that oxidative stress is significant in Down syndrome fetuses. Proc Natl Acad Sci U S A 106:9425–9429
Busciglio J, Yankner BA (1995) Apoptosis and increased generation of reactive oxygen species in Down’s syndrome neurons in vitro. Nature 378:776–779
Busciglio J, Pelsman A, Wong C, Pigino G, Yuan M, Mori H, Yankner BA (2002) Altered metabolism of the amyloid beta precursor protein is associated with mitochondrial dysfunction in Down’s syndrome. Neuron 33:677–688
Wang C, Youle RJ (2009) The role of mitochondria in apoptosis*. Annu Rev Genet 43:95–118
Helguera P, Seiglie J, Rodriguez J, Hanna M, Helguera G, Busciglio J (2013) Adaptive downregulation of mitochondrial function in down syndrome. Cell Metab 171:132–140
Pfeiffer M, Kayzer EB, Yang X, Abramson E, Kenaston MA, Lago CU, Lo HH, Sedensky MM, Lunceford A, Clarke CF, Wu SJ, McLeod C, Finkel T, Morgan PG, Mills EM (2011) Caenorhabditis elegans UCP4 protein controls complex II-mediated oxidative phosphorylation through succinate transport. J Biol Chem 286:37712–37720
Garcia O, Torres M, Helguera P, Coskun P, Busciglio J (2010) A role for thrombospondin-1 deficits in astrocyte-mediated spine and synaptic pathology in Down’s syndrome. PLoS One 5:e14200
Iwamoto T, Yamada A, Yuasa K, Fukumoto E, Nakamura T, Fujiwara T, Fukumoto S (2009) Influences of interferon-gamma on cell proliferation and interleukin-6 production in Down syndrome derived fibroblasts. Arch Oral Biol 54:963–969
Nickoloff BJ, Riser BL, Mitra RS, Dixit VM, Varani J (1988) Inhibitory effect of gamma interferon on cultured human keratinocyte thrombospondin production, distribution, and biologic activities. J Invest Dermatol 91:213–218
Maheshwari RK, Banerjee DK, Waechter CJ, Olden K, Friedman RM (1980) Interferon treatment inhibits glycosylation of a viral protein. Nature 287:454–456
Kanavin OJ, Aaseth J, Birketvedt GS (2000) Thyroid hypofunction in Down’s syndrome: is it related to oxidative stress? Biol Trace Elem Res 78:35–42
Kennedy RL, Jones TH, Cuckle HS (1992) Down’s syndrome and the thyroid. Clin Endocrinol (Oxf) 37:471–476
Chen MH, Chen SJ, Su LY, Yang W (2007) Thyroid dysfunction in patients with Down syndrome. Acta Paediatr Taiwan 48:191–195
Carroll KN, Arbogast PG, Dudley JA, Cooper WO (2008) Increase in incidence of medically treated thyroid disease in children with Down syndrome after rerelease of American Academy of Pediatrics Health Supervision guidelines. Pediatrics 122:e493–e498
Lott IT (2012) Antioxidants in Down syndrome. Biochim Biophys Acta 1822:657–663
Shichiri M, Yoshida Y, Ishida N, Hagihara Y, Iwahashi H, Tamai H, Niki E (2011) alpha-Tocopherol suppresses lipid peroxidation and behavioral and cognitive impairments in the Ts65Dn mouse model of Down syndrome. Free Radic Biol Med 50:1801–1811
Tiano L, Busciglio J (2012) Mitochondrial dysfunction and Down’s syndrome: is there a role for coenzyme Q(10)? Biofactors 37:386–392
Tiano L, Padella L, Santoro L, Carnevali P, Principi F, Brugè F, Gabrielli O, Littarru GP (2012) Prolonged coenzyme Q10 treatment in Down syndrome patients: effect on DNA oxidation. Neurobiol Aging 33(626):e1–e8
Miles MV, Patterson BJ, Chalfonte-Evans ML, Horn PS, Hickey FJ, Schapiro MB, Steele PE, Tang PH, Hotze SL (2007) Coenzyme Q10 (ubiquinol-10) supplementation improves oxidative imbalance in children with trisomy 21. Pediatr Neurol 37:398–403
de la Torre R, Dierssen M (2012) Therapeutic approaches in the improvement of cognitive performance in Down syndrome: past, present, and future. Prog Brain Res 197:1–14
Fowler PB, McIvor J, Sykes L, Macrae KD (1996) The effect of long-term thyroxine on bone mineral density and serum cholesterol. J R Coll Physicians Lond 30:527–532
Thiel R, Fowkes SD (2007) Down syndrome and thyroid dysfunction: should nutritional support be the first-line treatment? Med Hypotheses 69:809–815
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer-Verlag Wien
About this chapter
Cite this chapter
Torres, M.D., Busciglio, J. (2014). Down Syndrome. In: Lammert, E., Zeeb, M. (eds) Metabolism of Human Diseases. Springer, Vienna. https://doi.org/10.1007/978-3-7091-0715-7_10
Download citation
DOI: https://doi.org/10.1007/978-3-7091-0715-7_10
Published:
Publisher Name: Springer, Vienna
Print ISBN: 978-3-7091-0714-0
Online ISBN: 978-3-7091-0715-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)